(ACET) Adicet Bio - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0070021086
ACET: Gamma Delta T Cell, CAR Therapies, Cancer, Autoimmune Diseases
Adicet Bio, Inc. is a clinical-stage biotechnology company specializing in the development of allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The companys proprietary platform leverages gamma delta T cells, a unique subset of immune cells with inherent tumor-seeking properties, to engineer chimeric antigen receptor (CAR) T cell therapies. These therapies are designed to enhance persistence and activity in patients, addressing the limitations of traditional autologous CAR T cell therapies. Adicets lead candidate, ADI-001, is an allogeneic gamma delta T cell therapy targeting CD20, currently in Phase I clinical trials for autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkins lymphoma. The company is also advancing ADI-270, an armored gamma delta CAR T cell product candidate targeting CD70, with potential applications in renal cell carcinoma and other CD70+ solid tumor and hematological malignancies. Founded in 2014 and headquartered in Boston, Massachusetts, Adicet Bio is focused on expanding its pipeline to address unmet medical needs in oncology and autoimmune diseases.
Based on the provided
Additional Sources for ACET Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ACET Stock Overview
Market Cap in USD | 72m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Health Care Distributors |
IPO / Inception | 2018-01-26 |
ACET Stock Ratings
Growth 5y | -87.4% |
Fundamental | -53.4% |
Dividend | 0.0% |
Rel. Strength Industry | -60.4 |
Analysts | 4.43/5 |
Fair Price Momentum | 0.47 USD |
Fair Price DCF | - |
ACET Dividends
No Dividends PaidACET Growth Ratios
Growth Correlation 3m | -49% |
Growth Correlation 12m | -84.7% |
Growth Correlation 5y | -76.2% |
CAGR 5y | -34.91% |
CAGR/Max DD 5y | -0.36 |
Sharpe Ratio 12m | -2.42 |
Alpha | -75.82 |
Beta | 1.51 |
Volatility | 76.27% |
Current Volume | 120.3k |
Average Volume 20d | 381.7k |
As of March 17, 2025, the stock is trading at USD 0.78 with a total of 120,325 shares traded.
Over the past week, the price has changed by +2.57%, over one month by -19.32%, over three months by -18.70% and over the past year by -59.87%.
No, based on ValueRay Fundamental Analyses, Adicet Bio (NASDAQ:ACET) is currently (March 2025) a stock to sell. It has a ValueRay Fundamental Rating of -53.35 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ACET as of March 2025 is 0.47. This means that ACET is currently overvalued and has a potential downside of -39.74%.
Adicet Bio has received a consensus analysts rating of 4.43. Therefor, it is recommend to buy ACET.
- Strong Buy: 5
- Buy: 0
- Hold: 2
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, ACET Adicet Bio will be worth about 0.5 in March 2026. The stock is currently trading at 0.78. This means that the stock has a potential downside of -32.05%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 6.4 | 720.5% |
Analysts Target Price | 6.4 | 720.5% |
ValueRay Target Price | 0.5 | -32.1% |